Skip to content

Bifidobacterium bifidum reduce postoperative refractive discomfort through the gut-eye-lacrimal axis: a randomized, double-blind, placebo-controlled clinical trial.

Bifidobacterium bifidum reduce postoperative refractive discomfort through the gut-eye-lacrimal axis: a randomized, double-blind, placebo-controlled clinical trial.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085919
Enrollment
Unknown
Registered
2024-06-21
Start date
2024-06-21
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The cornea and ocular surface diseases

Interventions

Sponsors

The second affiliated hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) conform to the FS - LASIK surgery indications, diopter (D) not more than 10.00 spherical myopia, astigmatism is less than 5.00D, obvious refractive stability (spherical or cylindrical increase of less than 0.50D per year) in the last 2 years, intraocular pressure =21 mmHg. (2) Age of 18-45 years old, male or female. (3) During the treatment, patients could actively cooperate with routine surgical medication and probiotic therapy according to the course of treatment. (4) Informed consent was obtained from patients and their families. Note: The patients were included in this study if all the above four criteria were met

Exclusion criteria

Exclusion criteria: (1) conform to the absolute and relative contraindications to FS-LASIK, suffering from severe dry eyes, clear corneal scar, Angle, cornea expansion, rest after laser ablation substrate thickness < 250 µm, active ocular or systemic diseases, glaucoma or retinal disease, serious systemic illness, history of eye surgery, pregnancy or lactation." (2) patients with severe organ diseases. (3) the immune system defects. (4) patients allergic to the drugs used in this study. (5) patients with resistance to related research work and poor compliance. Note: conform to any of the above, are excluded

Design outcomes

Primary

MeasureTime frame
The incidence and severity of dry eye;

Secondary

MeasureTime frame
Corneal healing degree;visual quality;Intestinal microbiota homeostasis;Eye surface microbial homeostasis;

Countries

China

Contacts

Public ContactYifeng Yu

The second affiliated hospital of Nanchang University

171018170@qq.com+86 139 7918 0258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026